Top 5 Shipping Stocks To Watch For 2014

United Parcel Service (UPS) announced big changes at the top of the company’s management structure today.

Agence France-Presse/Getty Images

United Parcel Service named Chief Operating Officer David Abney as its next CEO to replace Scott Davis, who will remain chairman.

The changes come at a time of intense competition in the industry. The Wall Street Journal explains:

Meanwhile, competition in the shipping industry is likely to increase as a number of retailers like�Amazon.com�Inc. (AMZN) and�Wal-Mart Stores�Inc. (WMT) test their own delivery networks.�FedEx�Corp. (FDX) likely added fuel to that fire when it unveiled plans last month to change the way it charges to ship bulky packages, effectively increasing prices on more than a third of its U.S. ground shipments.

Instead of charging by weight alone, all FedEx ground packages will be priced according to size, which boosts the priced for delivering items as diverse as diapers, shoes and paper towels. The change in pricing could dramatically affect either online shoppers or retailers or both as one of the parties will have to swallow the estimated hundreds of millions of dollars in extra shipping costs.

5 Best Prefered Stocks To Own Right Now: Oppenheimer Holdings Inc.(OPY)

Oppenheimer Holdings Inc., through its subsidiaries, operates as a middle-market investment bank and full service broker-dealer. It offers full-service brokerage services covering various investment alternatives, such as exchange-traded and over-the-counter corporate equity and debt securities, money market instruments, exchange-traded options and futures contracts, municipal bonds, mutual funds, and unit investment trusts. The company also provides financial and wealth planning services; margin lending; securities lending; and online equity investing and discount brokerage services. In addition, it offers asset management services for equity, fixed income, large-cap balanced, and alternative investments offered through vehicles, such as privately managed accounts, and retail and institutional separate accounts. Further, the company provides strategic advisory services and capital markets products; institutional equity sales and trading; equity research; equity options and derivatives; convertible bonds; and event driven sales and trading services. Additionally, it trades in non-investment grade public and private debt securities, mortgage-backed securities, sovereign and corporate debt, and distressed securities; provides fixed income research, public finance, and municipal trading services; and is involved in proprietary trading and investment activities. The company also participates in loan syndications and operates as underwriting agent in financing transactions; trades syndicated corporate loans in the secondary market; offers various trust services; and provides mortgage services to developers of commercial properties. It serves high-net-worth individuals and families, corporate executives, small and mid-sized businesses, endowments and foundations, and institutions in the United States, Europe, the Middle East, Asia, and South America. The company was founded in 1977 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Hilary Kramer]

  With this news, some Wall Street firms finally ��albeit a bit late ��jumped on the ICPT bandwagon.� Citigroup (C) raised its target to $400, stating that its market cap (at the time $5.4 billion) didn�� reach the opportunity for these liver disease treatments.� They estimated that the OCA could exceed a $5 billion sales level.� Oppenheimer (OPY) also raised its target to $360 while Bank of America/Merrill’s (BAC) target is set at $872, the only one not yet exceeded with the most recent move.

• [By Ben Rooney]

  Tamayo then handed that information over to Vladimir Eydelman, a stock broker at Oppenheimer (OPY) and Morgan Stanley (MS). Eydelman in turn used it to trade stocks for Tamayo and other customers.

Top 5 Shipping Stocks To Watch For 2014: Archer-Daniels-Midland Company(ADM)

Archer Daniels Midland Company procures, transports, stores, processes, and merchandises agricultural commodities and products in the United States and internationally. It operates in three segments: Oilseeds Processing, Corn Processing, and Agricultural Services. The Oilseeds Processing segment engages in originating, merchandising, crushing, and processing oilseeds, such as soybeans, cottonseed, sunflower seeds, canola, rapeseed, peanuts, flaxseed, and palm into vegetable oils and protein meals. This segment also produces edible soy protein products, including soy flour, soy grits, soy protein concentrates, soy isoflavones, and soy isolates that are used in processed meats, baked foods, nutritional products, snacks, and dairy and meat analogs. The Corn Processing segment involves in corn wet milling and dry milling activities; and produces alcohol, amino acids, and other specialty food and animal feed ingredients, as well as ethyl alcohol. This segment also produces citr ic and lactic acids, lactates, sorbitol, xanthan gum, and glycols that are used in various food and industrial products, as well as astaxanthin, a product used in aquaculture to enhance flesh coloration. The Agricultural Services segment buys, stores, cleans, and transports agricultural commodities, such as oilseeds, corn, wheat, milo, oats, rice, and barley, as well as resells these commodities as food and feed ingredients for the agricultural processing industry. This segment also processes and distributes edible beans, formula feeds, and animal health and nutrition products. In addition, the company engages in milling wheat, corn, and milo into flour, as well as produces bakery products and mixes, wheat starch, gluten, and cocoa products that are sold to the baking industry; and involves in financial activities related to private equity fund investments, and futures commission merchant activities. Archer Daniels Midland Company was founded in 1898 and is based in Decatur, Illinois.

Advisors' Opinion:

• [By Rob Taylor]

  SYDNEY--Australia blocked a 3.0 billion Australian dollar (US$2.7 billion) bid by U.S. agribusiness company Archer Daniels Midland Co. (ADM) to buy grain handler GrainCorp. Ltd. (GNC.AU) on grounds that a takeover would go against the national interest.

• [By Anora Mahmudova]

  Archer Daniels Midland Co.�� (ADM) fourth-quarter adjusted earnings beat expectations. Shares gave up earlier gains and were 1.1% lower.

Top 5 Shipping Stocks To Watch For 2014: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:

• [By Brian Orelli]

  Most recently Elan (NYSE: ELN  ) spun out its drug discovery business into Prothena. Without the burden of a drug discovery unit, the parent company is now being pursued by Royalty Pharma, although Elan isn't keen on its current offer.

• [By Sofia Horta e Costa]

  Bellway Plc (BWY) added 1.4 percent after the homebuilder said reservations in the past four months rose 31 percent as buyers had greater access to mortgages. Elan (ELN) Corp. jumped to a 10-month high in Dublin after Royalty Pharma increased its offer for the Irish drugmaker to as much as $6.7 billion. BT Group increased 3.7 percent as Barclays Plc recommended investors buy shares of the U.K.�� largest fixed-line company.

Top 5 Shipping Stocks To Watch For 2014: Telefonica SA(TEF)

Telefonica, S.A. provides fixed and mobile telephony services primarily in Spain, rest of Europe, and Latin America. Its fixed telecommunication services include PSTN lines; ISDN accesses; public telephone; local, domestic, and international long distance and fixed-to-mobile communications; corporate communications; video telephony; supplementary and business-oriented value-added services; network services; leasing and sale of handset equipment; and telephony information services. The company?s Internet and broadband multimedia services comprise Internet service provider service; portal and network services; retail and wholesale broadband access; narrowband switched access to Internet; naked ADSL, a broadband connection; residential-oriented value-added services; companies-oriented value-added services; television services, such as IPTV, cable television, and satellite television; and Fiber to the Home, a service for high speed Internet access and digital video recording. Its data and business-solutions services principally include leased lines; virtual private network services; fiber optics services; the provision of hosting and application; outsourcing and consultancy services; desktop services; and system integration and professional services. The company?s wholesale services for telecommunication operators primarily comprise domestic interconnection services; international wholesale services; leased lines for other operators? network deployment; local loop leasing under the unbundled local loop regulation framework; and bit stream services. It also offers various mobile and related services and products that include mobile voice services, value added services, mobile data and Internet services, wholesale services, corporate services, roaming, fixed wireless, and trunking and paging services. The company has a strategic alliance with China Unicom (Hong Kong) Limited. Telefonica, S.A. was founded in 1924 and is headquartered in Madrid, Spai n.

Advisors' Opinion:

• [By LarryZ6]

  With the recent acquisition, financed by the $ 130 billion sale of Verizon Wireless (VZ) in the US, Vodafone adds 1.9 million clients to its customer base in Spain totaling 17.2 million, second to Tel茅fonica (TEF), which counts 24.9 million, and ahead of ORANGE (ORAN), that has 14.4 million customers. According to Antonio Coimbra, Vodafone麓s CEO in Spain, there are strong indicators that favor the acquisition:

• [By Dan Caplinger]

  You can see the same trends among many individual European stocks. Telecom giant Telefonica (NYSE: TEF  ) has big exposure to Latin America, but investors focus on its home country of Spain in limiting its gains. The same trend has affected French oil giant Total (NYSE: TOT  ) , which shares the same exposure to energy projects around the world yet has been tarnished by its proximity to the crisis-ridden continent. By focusing on value rather than perception, you can get some great values when others are being irrational.

• [By Charles Sizemore]

  So, what does this mean for AMX stock and for its largest single competitor in Latin America, Spain��Telefonica (TEF)?

  To start, this will, by default, massively diversify AMX�� revenue stream globally. Though AMX is the number-one or number-two mobile provider in nearly every Latin American country, its home market of Mexico is by far its biggest. Mexico currently accounts for about a third of sales and nearly half of profits. The new AMX will be a pan-Latin-American telecom giant based in Mexico rather than a Mexican telecom giant with operations in Central and South America.

• [By Roger Conrad, Founder and Chief Editor, Capitalist Times]

  Roger Conrad: Well, one that I read about actually in the very first issue of Conrad's Utility Investor is a company called Telefonica (TEF). This one is a company that has had a pretty tough several years.